Syngene Tech – Read Up on the Technology and Innovation Behind the Company

    There are a few reasons why you may be interested in reading up on the technology and innovation behind Syngene. The company’s initial focus was on sustainability, and it began with a temporary clinic in a government school after classes ended. Later, the clinic program expanded to eight full-fledged clinics in underdeveloped areas. Syngene then focused on technology and innovation, and developed eLAJ Smart Clinics.



    While other biotech companies outsource their tech support, Syngene has a team of engineers who develop all of their hardware and software in-house. Their team of imaging experts can quickly resolve problems with their systems. If you’re looking for quick answers to common questions, the company’s technical support library includes Application notes, Technical articles, FAQ’s and Quick Guides. With this in-depth technical support library, you can quickly find the answers to your questions and get back to work on your research.

    Syngene International Ltd. is a contract research and manufacturing organization headquartered in Bangalore, India. Syngene offers research and development services for clinical supplies, R&D, and custom synthesis. The company offers a range of services in the pharmaceutical industry, including custom synthesis, process R&D, regulatory filing, and chromatographic purification. They also offer manufacturing and formulation services for high-potency active pharmaceutical ingredients.


    Syngene news

    While a company’s growth may depend on the size and scope of its portfolio, the company is still relatively small. The company’s technology is largely focused on medical research and development. Its portfolio includes diagnostic, imaging, and drug development services. Syngene’s research services segment reported revenue of Rs422 crore, a flat year-on-year comparison. However, management is confident that the company can continue to grow at double-digit rates.

    In the past quarter, the company has boosted its revenue guidance and renewed business commitments with existing clients. Its focus on the commercialization of drugs has also led to renewed investment in its discovery services. It also intends to add a new sterile fill finish facility to its Bangalore campus. The new facility will be fully automated and digitally driven. Eventually, the company hopes to sell its intermediate products and sell them in the market.

    The new facility includes two fermenters of 200 and 500 liters, which will enhance the company’s biomanufacturing capabilities and strengthen its service offerings for biopharmaceutical companies. Syngene’s expansion builds on its existing biopharmaceuticals manufacturing capabilities, and the company plans to increase its team to 600 scientists in the next six months. Syngene is committed to increasing its client retention rate to 90%.


    Syngene international limited

    As the name suggests, Syngene International Limited is in the business of providing healthcare services. Its core activities include the operations of general and specialty hospitals, sanatoria and asylums, rehabilitation centers and dental clinics, and military base hospitals. The company is listed on the New York Stock Exchange under the sector HEALTH AND SOCIAL WORK. It has a solid corporate governance structure. The company’s infrastructure is adequate and up-to-date.

    The company has a team of more than 4,200 highly qualified research scientists and engineers who have been recruited from leading academic and industry research institutions around the world. Syngene has a strong reputation for attracting and retaining premium talent and has invested in state-of-the-art infrastructure and systems. Moreover, its research capabilities include hit identification techniques and in vivo capabilities in non-human primates. Its Research Services division delivered steady results and added new client projects across multiple modalities.

    The research capabilities of Syngene International Limited cover drug product development and clinical supplies. Their capabilities span the biomedical fields of medicinal chemistry, biology, in vivo pharmacology, and toxicology. They also offer custom synthesis and clinical development services. For biopharmaceutical companies, they can provide services such as drug development and preclinical testing, target validation, and translational interrogation. The company has partnered with Biocon Limited and Bristol-Myers Squib Co.


    Syngene products list

    The Syngene tech products list includes instruments, systems, and software for a variety of molecular biology applications. Scientists studying DNA, RNA, and proteins need to understand the underlying processes to make discoveries. Many laboratories rely on gel electrophoresis for this fundamental process. Syngene offers everything from entry-level kits to sophisticated, computer-controlled analysers. Its extensive product line also includes instruments and software for fluorescence, chemiluminescence, proteomics, and genomics research.

    The company has become a successful company in the biotechnology space. With an impressive list of clients, Syngene’s revenue has increased by 15% in four years. Some of the companies on its client list include Bristol Myers Squibb, Amgen, Herbalife, GlaxoSmithKline, Baxter International, and Zoetis. Its client retention rate is also high, topping 90%.

    Syngene is expanding its service platforms to include development batches and large-scale commercial supplies. The company’s R&D and development arm has grown by leaps and bounds, with its integrated operating model driving growth. With its latest acquisitions, Syngene is aiming for USD 250 million in revenue in FY18. In the meantime, it’s continuing to expand its product line, adding new technologies and services to its portfolio.

    Syngene products

    In the contract research and manufacturing sector, Syngene International Ltd. offers services in process R&D, custom synthesis, formulation services, and clinical supplies. Headquartered in India, Syngene International Ltd.’s business focuses on supporting the discovery and development processes of global pharmaceutical and biotech companies. These services include bioinformatics, organic chemistry, and discovery chemistry and biology. Moreover, the company’s services help clients discover, develop, and manufacture novel drugs and biotechnology products.

    Among Syngene’s portfolio, the company offers scientific instruments, software, and systems to help scientists make sense of complex biological samples. For example, its GeneSys software helps scientists capture excellent images of complicated gels. It also supplies GeneTools software, which features advanced band matching facilities. The company’s GeneDirectory data storage facility is also well-suited for large-scale genomic fingerprinting studies. These products are available to help scientists identify the genetic material that is responsible for disease.

    Syngene login

    Syngene International Ltd is a contract research and manufacturing company based in India. Its services include protein and gene synthesis, drug discovery, and clinical supplies. Its research and development programs benefit from its outstanding technical expertise and support. According to CB Insights, the company has filed 11 patents and has an impressive track record of success. With a current market capitalization of around $600 million, it has no shortage of opportunities to grow.

    The company is an integrated research, development, manufacturing, and supply services provider to the global pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries. The companys 4700 scientists provide great science, robust data management, quality manufacturing at speed, and robust IP security. Syngene is home to a world-class facility with more than 2 million square feet of dedicated specialist discovery. To learn more about its services, sign up for Syngene Tech Login.

    Syngene company

    In a world that is characterized by high-tech, global competition, and a fragmented workforce, Syngene has an impressive list of corporate attributes. With over 4,200 scientists and research scientists, the company is consistently attracting top talent. Its investments in state-of-the-art infrastructure and world-class systems enable it to provide global clients with cutting-edge scientific solutions. Moreover, the company is well-known for its unified culture, which fosters innovation and productivity.

    For instance, the company’s Development Services unit has bolstered its capabilities and collaboration with the pharmaceutical industry. With extensive drug discovery experience, Syngene has developed services that extend beyond custom synthesis and target validation. Its capabilities encompass all aspects of drug discovery, from early target identification to preclinical evaluation and from drug substance to drug product preparation. With this, the company can address the growing demand of pharmaceutical companies and expand its customer base.

    Syngene pharma products

    The technology pharma company Syngene was founded in 1993 as a part of biopharmaceutical giant Biocon Limited and has since expanded to five-thousand employees – including nearly four thousand scientists. The company offers end-to-end drug discovery, research, and development services for global pharmaceutical companies. The company went public on the bourses in 2015 and has an impressive client list of more than 400. However, many companies are reluctant to outsource important drug discovery work due to concerns about limiting their own internal resources.

    As part of the company’s commitment to research and development, Syngene has also partnered with leading companies in the pharmaceutical industry. This includes clients such as Bristol-Myers Squibb, Amgen, GSK, and Herbalife. The company’s innovative approach and global mindset have helped it secure a prestigious client list. Its expertise in biomanufacturing liquid injectables is an asset to its clientele.


    The Advantages of Using Sygene Tech Support

    Syngene has a highly-regarded technical support team, which is one of the best in the business. Its imaging developers and applications engineers are available to help with any questions you may have. In addition to quick response times, its extensive library of technical articles, Application notes and FAQ’s also provide an excellent source of information for users. Read on to discover the advantages of using Syngene technical support. Let us take a look at what these benefits can mean for your business.


    As one of the leading suppliers of gel documentation systems, Syngene is well known for its outstanding technical support. The company is dedicated to delivering unparalleled service support and technical expertise to its customers. According to CB Insights, Syngene has filed 11 patents and holds millions of data points. If you’re interested in advancing your career in molecular biology, consider applying for a position at Syngene.

    Founded in 1994, Syngene International Ltd. is an integrated contract research and manufacturing services organization. Its expertise spans across organic and synthetic chemistry, custom synthesis, cGMP manufacturing, and formulation services. In addition, Syngene’s dedicated lab will scale small molecules. This facility will also house a team of 250 scientists to provide the highest quality research and development for clients. The company’s expertise and resources will ensure that customers get the right drug solutions, the first time.


    Sygene Tech Biocon, a publicly traded subsidiary of Biocon, is a contract research organization that provides manufacturing and contract drug discovery services for 17 of the world’s largest pharmaceutical companies. The company began as a generic drug exporter to the United States. In recent years, it has grown its revenue by 25 percent. It is currently investing in its biosimilars program and is expanding its manufacturing capacity. Its revenue has increased 25 percent over the past three years.

    During the third quarter of 2018, Biocon announced it had completed the purchase of 40 acres in a special economic zone to develop commercial facilities. Biocon plans to build the facility with a capacity of more than a billion dollars. The company will use the land to produce therapeutic antibodies and other drugs for various ailments. The purchase is expected to result in an increase of profits for Biocon as the company anticipates double-digit revenue growth over the next five years.

    During the fourth quarter of its 2017 fiscal year, the company faced a fire at its Bengaluru facility. The fire has reduced its revenues. As a result, Syngene’s stock price fell. However, it remains optimistic about achieving double-digit revenue growth throughout the rest of the year. This is an indication of the company’s confidence in its ability to conduct high-quality scientific research. And, Syngene is well positioned to capitalize on the emerging trends in gene therapy and biotechnology.

    Sygene Tech Biocon’s track record of commercialisation is impressive. The company has successfully brought a portfolio of biopharmaceuticals to market, including blockbusters like Insulin, Statin, and Immunosuppressants. Its portfolio also includes a number of Biogenerics. It also works on a novel medicine. Biocon markets a diverse portfolio of branded products in India.

    Biologics manufacturing

    The first step to achieve synergy between Syngene’s biologics manufacturing capabilities and its commercial business pipeline is to retain key customers and create a robust Scientific Advisory Board for emerging platforms. Once this process has been completed, Syngene will then pursue commercial manufacturing opportunities in the non-regulatory generics market. It will also have to invest in its people and technology to achieve robust operating performance. The investments will result in improved yields, lower COGS and faster cell to clinic timelines.

    The company has already contributed to the development of Albireo Pharma’s drug that treats genetic liver disease in children. It has conducted several campaigns for the drug substance, including phase-III clinical trials. This will enable Syngene to focus on developing its microbial manufacturing facility. In addition, Syngene has recently entered into new contracts for animal health biologics development. Its investments in R&D and manufacturing have paid off in terms of new client wins.

    As part of the expansion, the company has built a new microbial cGMP facility and expanded its existing mammalian cell manufacturing facility. The new facility features two fermenters of 200 litres and 500 litres. This expansion is expected to create additional integration opportunities and extend the company’s service offering. The new facility will be located in India, in Bengaluru. Syngene plans to expand its service offerings by incorporating the new facility into their current operations.

    The company’s new Bangalore biotechnology manufacturing facility has the ability to cater to a range of clients, including those in early-stage development, commercial-scale production, and discovery services. With an 86 percent client base in the United States, the company is poised for continued growth. Syngene also expects to invest $100-120 million in the facility in FY22. The company also plans to add a new sterile fill finish facility.


    If you want to be a part of the growing technology world, you should consider pursuing an education at Syngene. Our program offers a unified culture and a variety of career opportunities. As part of our CSR efforts, we provide quality education to schoolchildren in need. We started with mathematics workbooks and then expanded to other subjects. In fact, the education department has requested the use of our books in government schools. We’ve also trained ASHAs, and have equipped them with mobile apps, which help them to identify potential patients and then mobilise them for further diagnosis.

    As the company expands its services and infrastructure, it’s acquiring new companies to expand its expertise. The company is currently looking for opportunities to accelerate the development of its pipelines and accelerate drug development. Its current focus is on CAR-T cells and siRNA, as well as antibody-drug conjugates and PROTAC (drugs that degrade a targeted protein). The company’s future plans include investing $100-120 million to expand its biomanufacturing capabilities.

    Syngene International Ltd. is a contract research and manufacturing company based in India. They provide scientific research, development, and manufacturing services to major industries across the world. Syngene’s 4500+ scientists combine innovative science with robust data management and quality manufacturing to help clients accelerate their time to market. The company’s dedicated facilities include Amgen and Bristol-Myers-Squib laboratories. In addition, it is committed to improving the lives of animals and people worldwide through the development of novel therapeutics.

    Bristol Myers Squibb and Syngene International have a longstanding research collaboration that began in 1998. This collaboration will include the full range of drug discovery and translational medicine research for the companies. Dedicated laboratory space will be added to the facility to enhance research and development. The company’s R&D capabilities are expanding throughout Asia and will provide a solid value-added capability base to their clients. So, if you are considering starting a career in the pharmaceutical industry, Sygene is the place to be.

    Partnership with NIMHANS

    The partnership between Syngene and NIMHANS is designed to help improve patient outcomes and reduce the cost of drug discovery. Syngene is a structure-based drug discovery company, and will provide a one-stop shop with the expertise and knowledge necessary to find and develop new medicines. In addition, the collaboration will improve the efficiency of the drug discovery process. The company’s research facility is located in the heart of Bengaluru.

    The partnership between Syngene Tech and NIMHANS will focus on the development of new therapies for brain health problems. During the past year, the company has invested in state-of-the-art facilities and world-class systems. Its technology and IT systems have enabled it to meet global compliance standards and respond to client needs and requirements. While NIMHANS is the flagship of Syngene’s Discovery Services division, the company continues to invest in new technology and partnerships.

    Syngene Tech has expanded its partnership with Development Services, a fully integrated drug discovery service provider. Syngene’s extensive drug discovery knowledge allows it to support a broad range of clients through the drug discovery process, from target identification and validation to preclinical evaluation and manufacturing. The partnership with NIMHANS also supports the Bangalore Urban Mental Health Initiative and the development of self-care health kits.

    Syngene has a proven track record. The company’s global infrastructure is equipped for disaster recovery and business continuity. Its rigorous governance practices ensure its ability to successfully deliver on its commitments. Its team is comprised of highly skilled scientists and has a culture of ethics and integrity. Syngene’s corporate governance model emphasizes quality, safety and integrity. The company’s scientific skills and cost competitiveness enable it to deliver significant value to customers.

    Latest articles


    Related articles

    Leave a reply

    Please enter your comment!
    Please enter your name here